INTRODUCTION
Cytochromes P450 (CYPs) belong to a protein superfamily among which some members metabolize polyunsaturated long-chain fatty acids (PUFA-LC) to several classes of oxygenated metabolites. The products profiles depend on the involved CYP isoforms and may consist of a series of regio-and stereo-isomeric epoxides and hydroxylated compounds (1) (2) (3) .
In humans, CYP isoforms from family 1 to 3 are mainly epoxygenases whereas CYP isoforms from family 4 are mainly ω-hydroxylases (4, 5) .
CYP epoxygenases convert arachidonic acid (AA) to four epoxyeicosatrienoic acid regioisomers (5, 8, 11, and 14, , that function as lipid mediators. EETs produce vascular relaxation, have anti-inflammatory effects on blood vessels and in the kidney, promote angiogenesis and protect ischemic myocardium and brain (for review see (6) (7) (8) . CYP epoxygenases also convert the ω3-PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to epoxy-derivatives (9) which are potent dilators of coronary arterioles (10) (11) (12) or pulmonary artery (13) and inhibit platelet aggregation (14) . The EPAderived epoxides account for five epoxyeicosatetraenoic acids (5,6-, 8,9-, 11,12-, 14,15-, and 17,18-EETeTr) whereas the DHA-derived epoxides account for six epoxydocosapentaenoic acids (4, 7, 10, 13, 16, and 19, . A high regio-and stereo-selectivity has been observed when testing the effects of chemically synthesized epoxides from AA and EPA. For example, in the rat, renal arteries were dilated by 11(R),12(S)-EET but not by 11(S),12(R)-EET or 14,15-EET enantiomers (15) . Still in the rat, among all EETeTr enantiomers, only the 17(R),18(S)-enantiomer but not the 17(S),18(R) one, was effective on BK-channels in isolated cerebral arteries (11) . However, in porcine coronary microvessels, all regioisomeric EETeTrs had similar vasodilatory potencies (16) . Thus, the regio-and stereochemical features of the CYP-derived metabolites govern their biological activity and/or potency and functional significance. The biological activity of DHA epoxides regioisomers and enantiomers is still largely unknown as are the identity and reaction specificity of the individual CYP isoforms involved in EPA and DHA metabolisms (17) .
According to previous studies, CYP isoforms display different regioselectivities for PUFA hydroxylation and epoxidation. For example, CYP1A1 is mainly a hydroxylase towards AA whereas it acts primarily as epoxygenase towards EPA as substrate (18) . CYP102A1 (Bacillus Megaterium BM-3), a bacterial CYP that closely resembles eukaryotic microsomal P450s (19) is mainly an ω-hydroxylase for AA and a highly specific epoxygenase for EPA.
Replacement of phenylalanine 87 (F87) with valine (V) converts CYP102A1 into a highly specific AA epoxygenase (20) . Through use of human recombinant CYPs, we recently evidenced that CYP1A1, -2C19, -2D6, -2E1 and -3A4 are mainly hydroxylases of AA, EPA and DHA whereas CYP2C8, -2C9, -2J2 and -1A2 are mainly epoxygenases (21) . Epoxygenase regioselectivity depends on the nature of the unsaturated fatty acid of concern since four, five or six double bonds can be epoxidized. The number of epoxygenase products is increasing with the number of unsaturations, and the last double bond is preferentially oxidized i.e. ω6, in AA or ω3 in EPA and DHA, respectively. However, to our knowledge, the studies about the stereoselectivity of this epoxidation have only dealt with AA or EPA and a few CYPs (18, 20, (22) (23) (24) (25) (26) (27) (28) (29) ; none of them has been focused on DHA. Therefore, we have systematically investigated the stereochemistry of the epoxidation reaction of the last double bond of AA, EPA and DHA by 9 recombinant CYPs, with special emphasis on DHA epoxide enantiomers. The CYP102A1 F87V mutant was thus used as a model because of its high enantiofacial selectivity; indeed, it is known to epoxidize the si,re face of the last olefin of AA or EPA . This allowed us to identify, by comparison, the PUFAs epoxide enantiomers generated by the human recombinant CYPs. 
Recombinant CYPs and CYP102A1 F87V
Microsomes containing the human recombinant CYPs (CYP1A1, -1A2, -2C8, -2C9, -2C19, -2E1, -2D6, -2J2 and -3A4) (32) . 
Chemical synthesis of radiolabelled epoxides

Synthesis of radiolabelled epoxides by CYPs
All of the reaction mixtures were prepared in a final volume of 100 µL and contained 1 nmole 2E1, 3A4) these compounds were supplemented with cold substrate. After a 5 min preincubation at 37°C, the reaction was started by addition of 1 mM NADPH. Different substrate concentrations were used in order to avoid auto-inhibition previously described (21).
After 30 min, the reaction was stopped by addition of 0.1 mL acetonitrile containing 0.2% acetic acid (v/v). Fatty acids and their metabolites were twice extracted by 2 mL ethyl acetate.
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Samples dried under nitrogen were dissolved in 50 µL ethanol, and the metabolites were resolved by HPLC as described below.
Incubation with CYP 102A1 F87V: the reaction mixture contained 100 µM of AA, EPA or DHA and radiolabelled substrate, 10 µg of crude extract, 0.12 M phosphate buffer pH 7.4, and 5 mM MgCl 2 . After a 2 min pre-incubation at 30°C, the reaction was started by addition of 1 mM NADPH. After 2 min, the reaction was stopped by addition of 0.1 mL of a solution of acetonitrile with 0.2% acetic acid (v/v). Then, the samples were processed as above.
HPLC conditions
The monoepoxide or hydroxylated metabolites of fatty acids were separated by a reversed phase ion-pairing liquid chromatography as previously reported (9). Briefly, the regioisomers were separated isocratically on a RP-Capcell Pak C18, 120 Å, 250 mm x 4.6 mm, particle were collected. The samples acidified by 20 µL of acetic acid were twice extracted by 2 mL ethyl acetate and dried under nitrogen. Then, the methylation reaction was started by addition to the samples of 300 µL of diethylether saturated with diazomethane . After incubation for 15 min at room temperature, the samples were dried under nitrogen and redissolved into hexane prior to analysis by chiral HPLC.
HPLC-MS identification of epoxides
The epoxidized metabolites were separated under the HPLC conditions described above and identified by mass spectrometry (MS) on a mass spectrometer (Navigator model, ThermoElectron, Les Ulis, France) equipped with an ionisation source at atmospheric pressure (APCI) and operated in negative-ion mode. The cone voltage was optimized in the range 30-45V to enhance molecular fragmentation. The vaporiser temperature for APCI was 350°C and the source one at 150°C. The drying nitrogen flow was 352 L/h whereas the needle of the corona pin was set at 3 kV, the skimmer at 0.9 V and the quadrupole ion energy at 2.6 V. For epoxide identification, the negative ions were monitored in full scan mode in one second from m/z 50 to 600.
HPLC Chiral analysis
For chiral analysis, the standard reactions of incubation were repeated 3 to 7-fold. The products collected from the HPLC-runs i.e. 14,15-EETs, 17,18-EETeTr, or 19,20-EDP were pooled and derivatized with diazomethane to methylesters that were subsequently analyzed by chiral-phase HPLC on a Chiralcel OB column (250 × 4.6 mm; Daicel, Interchim, Montluçon, F). The solvent was hexane with 0.3% isopropyl alcohol and 0.05% (v/v) acetic acid and was delivered at a flow rate of 1 ml/min. The enantiomers were detected with a β-radiometric flow scintillation analyzer Flo-one 500Tr (Perkin-Elmer-Packard Biosciences, USA). The enantiomers were identified by comparison with known products generated by CYP102A1
F87V catalyst.
GC-MS identification of epoxides
The epoxidized samples were analyzed by GC-MS on an Agilent GC 6890 coupled to a 5973 MS Detector (Agilent,Les Ulis, France) and equipped with a DB-5MS column (low-bleeding, 5% phenyl/95% dimethylpolysiloxane phase) 30m×0.25mm I.D.×0.25µm film thickness (J&W Scientific, Agilent). The temperatures of the injection port and interface were 250 and 280°C, respectively; those of the ion source and MS analyzer were set at 150 and 106°C, respectively. The samples were injected in splitless mode. The oven temperature was, first, set at 60°C for 5 min, elevated to 230°C at the rate of 50°C/min and then to 290°C at 1°C/min.
The compounds were ionized by electron impact at 70eV energy. The carboxylic group of DHA monoepoxides was converted to methyl ester as previously described. The reaction solvent was dried under a nitrogen stream and redissolved in hexane prior to injection.
Analytes were detected by total ion current (TIC) from m/z 50 to 600. These mass spectra were identical to those generated under similar conditions by synthetic 16,17-or 19,20-EDP regioisomers (data not shown).
RESULTS
Regioselectivity of CYP isoforms and CYP
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However, the stereoselectivity of the epoxidation reaction by CYP isoforms is poorly known, especially when DHA is a substrate. The lack of commercially available enantiomeric standards for EDP prevents their easy characterization. This led us here to identify these enantiomers from the well-known stereoselectivity of CYP102A1 F87V (24) . CYP2C8 showed an opposite stereoselectivity of epoxidation of the AA ω6-and EPA ω3-olefins as the R,S enantiomer was mainly generated from AA and the S,R one from EPA.
Stereoselective epoxidation of the last double bond of DHA by CYP102A1 F87V and human recombinant CYPs
As expected, the biosynthesis of 19,20-EDP by CYP102A1 F87V was highly asymmetric and presumably generated the 19(S),20(R)-EDP enantiomer (87% optical purity) (Figure 3 ).
Identification of this enantiomer was based on the previously described C-H acceptor chemistry and active site-binding coordinates of CYP102A1 F87V known to preferentially deliver oxygen to the si,re-face of the last olefinic bond for both AA (ω6) and EPA (ω3) (24) . 
DISCUSSION
Little is known about the identity and reaction specificity of the individual CYP isoforms involved in EPA and DHA metabolisms (17) . The use of human recombinant CYPs,
allowed us to recently demonstrate that the epoxygenase/hydroxylase activity ratio (E/H) is dependent upon the nature of PUFAs and CYP isoforms (21) . However, with EPA and DHA, epoxygenase products were more abundant than with AA. Furthermore, the last double bond of the alkyl chain of AA (ω6), EPA (ω3) or DHA (ω3) was preferentially epoxidized. After a reassessment of the regiospecificity of AA-, EPA-and DHA-epoxidation of the last olefinic bond by human CYPs of families 1-3, we have characterized the stereochemistry of this reaction with special emphasis on DHA-epoxide enantiomers.
Regioselectivity of epoxidation
Depending on the nature of the PUFAs, four, five or six double bonds may be concerned by the regioselectivity of the epoxidation reaction. In this study, the preferentially oxidized double bond by CYP1A1, -1A2, -2D6, 2J2 and -2E1 was always the last one, i.e. 14,15 (AA), Thus, the metabolism of AA by CYP102A1 leads to the production of 18-OH-AA (main product) and 14,15-EET whereas the F87V mutant generates 14,15-EET as the sole reaction product. In our study, metabolism of EPA or DHA by CYP102A1 F87V generated a mixture of two regioisomers, namely the 14,15-and 17,18-EETeTr for EPA, as previously described (20) or the 16,17-and 19,20-EDPs for DHA. Thus, it appeared that the regioselectivity of the last olefin epoxidation was very similar for EPA and DHA as the ω3 and ω6 olefins were epoxidized in each case. Furthermore, it must be underlined that the preferred site of AA and EPA for catalyzed oxygen insertion by CYP102A1 is the (ω-2) carbon atom leading to 18-OH-AA and 17,18-EETeTr, respectively. This indicates that both fatty acids likely occupy more or less similar spatial coordinates in the enzyme active site.
Modelling experiments provide evidence for lowest interaction energies of the C20 fatty acid-CYP1A1 complexes when the substrates are docked in orientations leading to hydroxylation at C19 or electron abstraction at C18 and C17 (18) . Such energetic differences may explain the regioselectivity of CYP-mediated reactions (36) . It appears that flexible AA and EPA are stabilized in the active site mainly by hydrophobic interactions, thus governing the regiospecificity of substrate oxidation.
Stereoselectivity of epoxidation
The stereoselectivity of PUFA epoxidation was studied using CYP102A1 F87V as model because of its high enantioselectivity. Regardless of the fatty acid, the si,re faces of the last double bond, 14,15 or 17,18-olefin for AA and EPA, respectively, were always selected for epoxidation (20) . We assumed that epoxidation will also take place on the si,re face of the 19,20-olefin of DHA, given the similar regioselectivity established between EPA and DHA.
The absolute configurations of the regioisomers were assigned by chromatographic comparisons with enantiomerically pure methylated fatty acid epoxides prepared by total chemical synthesis (racemic mixture) and enzymatic epoxidation from the enantioselective CYP102A1 F87V. Furthermore, the chiral analysis by HPLC on Chiralcel OB showed that the S,R enantiomer epoxide of the last double bond of AA and EPA was eluted after its optical antipode as it was the case in all previous studies (18, 22, 23, 33, 37) . These results were verified with DHA epoxide enantiomers, namely the 19,20-EDP. It is worth underlining that the elution order was the opposite on Chiralcel OD (38) or Chiralcel OJ (28).
Our investigations showed that the epoxidation of the last double bond by most of the hepatic
CYPs is more stereoselective with the (ω3) PUFA (EPA or DHA) as substrates than with the (ω6) AA. Interestingly, CYP2C8 showed an opposite stereoselectivity of this reaction between AA and EPA or DHA. CYP2C9 epoxidized EPA with a lower regioselectivity for the last olefin than CYP2C8 as already reported (22) .The same was observed with DHA resulting in a decreased capacity of CYP2C9 to synthesise the 19,20-EDP. This prevented us to characterize the enantioselectivity of this reaction.
This study confirmed the previously described stereoselectivity of epoxidation catalyzed by the CYP2C (33, 39) and CYP1A1 (18) subfamilies in AA and EPA metabolisms. Whereas CYP102A1 F87V is known to epoxidize the si,re face of the last double bond of AA, EPA and DHA, CYP1A1, -1A2, -2E1, -2C19 and -2J2 proved to oxidize preferentially the re,si face during the metabolism of EPA or DHA. This difference suggests that these ω3-PUFAs were strictly positioned in the active site with the re,si face set in close vicinity of the ferryloxo complex of these CYPs. In our opinion, this positioning is governed by hydrophobic interactions, but not by the reactivity of the double bond hydrogens. In the case of CYP102A1, it has been suggested that the F87 residue blocks the ω-terminus of fatty acids (18) so that the si,re face is presented near to the ferryl-oxo complex. By analogy, the F equivalent residues of CYP1A1, -1A2, -2E1, and -2C19 might play the same role on blocking the ω-methyl terminus but in such position that the re,si face of double bond will be preferentially epoxidized.
Conclusion
A careful examination of the epoxidation reaction of the last double bond of the three substrates emphasizes high similarities in the stereoselectivity of EPA and DHA epoxidation by the 9 CYPs but noteworthy differences between the CYPs. The similarities are likely attributable to the position of the last double bond in such long-chain fatty acids; indeed, EPA and DHA belongs to the ω3 class, whereas AA is a member of the ω6 class. As attempts to get crystals of PUFAs-bound human CYPs have been unsuccessful till now, our experimental data were important because the enantioselective metabolism of PUFAs appears unpredictable from the sole knowledge of active site conformation.
The CYP-dependent metabolism of EPA and DHA is a source of physiologically active compounds that may contribute to the beneficial cardiovascular effects attributed to diets rich Results are expressed as percentages of the two enantiomers generated by incubation of AA (A) and EPA (B) with CYP102A1 F87V and human recombinant CYPs. Enantiomers were identified by comparison with the S,R enantiomer generated by CYP102A1 F87V. * CYP2J2 data were previously reported (42). Results are expressed as percentages of the two enantiomers generated by incubation of DHA with CYP102A1 F87V and human recombinant CYPs. Enantiomers were identified by comparison with the S,R enantiomer generated by CYP102A1 F87V. 
